Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Qtern

- PMLiVE

FDA approval for Keytruda/Herceptin combination in first-line advanced gastric cancer

Approval is based on positive overall response rate (ORR) data from KEYNOTE-811 trial

- PMLiVE

Eli Lilly/AbCellera’s COVID-19 variant-targeting antibody enters clinical trials

Drug will be evaluted alone and together with other monoclonal antibodies in the expanded BLAZE-4 trial

- PMLiVE

AstraZeneca reports ‘strong’ Q1 results, forecasts accelerated growth in 2021

Company is ‘well-positioned for a high growth year’, according to analyst

- PMLiVE

Lilly cuts 2021 guidance to reflect ‘lower expected revenue’ from COVID-19 antibody sales

FDA recently removed emergency authorisation for bamlanivimab monotherapy

- PMLiVE

AZ, Sanofi’s nirsevimab hits primary endpoint in RSV trial

Drug reduced lower respiratory tract infections caused by respiratory syncytial virus in infants

- PMLiVE

EU moves forward with legal action against AZ over vaccine supply issues

Legal proceeding launched on the basis of 'breaches of the advanced purchase agreement'

- PMLiVE

J&J resumes US rollout of single-dose COVID-19 vaccine

CDC and FDA recommended pause be lifted after ‘rigorous review’ of very rare blood clots

- PMLiVE

GSK wins approval for anti-PD-1 antibody Jemperli in endometrial cancer

AnaptysBio earns a $20m milestone payment on approval after originally developing the drug

- PMLiVE

EU may seek legal action against AstraZeneca following vaccine supply cuts

EU supply issues for the AZ vaccine started in January 2021

- PMLiVE

J&J halts manufacturing of COVID-19 at US plant after FDA warning

Inspection report found facility was “not maintained in a clean and sanitary condition”

- PMLiVE

Valneva to compare its COVID-19 vaccine candidate to AstraZeneca’s jab

Phase 3 trial will test Valneva’s vaccine candidate against Vaxzevria in approximately 4,000 participants

- PMLiVE

Lilly asks to revoke emergency authorisation for bamlanivimab monotherapy in the US

Decision prompted by the ‘evolving variant landscape’ in the US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links